We are live on
!
Find out more
Alphabet Inc Portfolio holdings
AUM
$99.1B
Turnover
13.79%
1-Year Est. Return
124.46%
This Fund
S&P 500
This Quarter
Est. Return
+30.24%
1 Year Est. Return
+124.46%
3 Year Est. Return
+326.82%
5 Year Est. Return
+231.24%
10 Year Est. Return
+1,201.66%
AUM
$2.16B
AUM Growth
+$600M
(+39%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
6%
Top 10 Holdings %
Top 10 Hldgs %
88.29%
Holding
46
New
1
Increased
4
Reduced
2
Closed
2
Avg Time Held
2.6
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$309M |
| 2 |
Revolution Medicines
RVMD
|
+$127M |
| 3 |
Verve Therapeutics
VERV
|
+$22.3M |
| 4 |
Neumora Therapeutics
NMRA
|
+$2.52M |
| 5 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
+$6 |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UiPath
PATH
|
+$137M |
| 2 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
+$106M |
| 3 |
Oscar Health
OSCR
|
+$88.7M |
| 4 |
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
|
+$208K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.64% |
| 2 | Technology | 47.2% |
| 3 | Industrials | 4.04% |
| 4 | Consumer Staples | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DexCom
DXCM
$31.5B
| $457M | 21.18% |
3,681,885
+3,027,031
| +462% | +$309M |
2018 Q4
20 quarters
|
|
2
CrowdStrike
CRWD
$255B
| $328M | 15.2% |
5,134,732
| – | – |
2022 Q4
4 quarters
|
|
|
3
UiPath
PATH
$6.81B
| $175M | 8.1% |
7,034,337
-7,034,337
| -50% | -$137M |
2021 Q2
10 quarters
|
|
|
4
DELISTED
Verve Therapeutics
VERV
| $172M | 7.98% |
12,349,086
+1,800,000
| +17% | +$22.3M |
2021 Q2
10 quarters
|
|
5
GitLab
GTLB
$8.86B
| $167M | 7.73% |
2,647,312
| – | – |
2022 Q2
6 quarters
|
|
|
6
Revolution Medicines
RVMD
$41.5B
| $152M | 7.05% |
+5,301,512
| New | +$127M |
2023 Q4
0 quarters
|
|
7
Arm
ARM
$254B
| $147M | 6.83% |
1,960,784
| – | – |
2023 Q3
1 quarter
|
|
8
Snowflake
SNOW
$118B
| $107M | 4.94% |
535,604
| – | – |
2022 Q1
7 quarters
|
|
9
Prime Medicine
PRME
$568M
| $105M | 4.87% |
11,862,498
| – | – |
2022 Q4
4 quarters
|
|
10
Freshworks
FRSH
$3.57B
| $94.8M | 4.4% |
4,035,595
| – | – |
2021 Q4
8 quarters
|
|
11
Planet Labs
PL
$5.14B
| $78.9M | 3.66% |
31,942,641
| – | – |
2021 Q4
8 quarters
|
|
12
Invivyd
IVVD
$179M
| $22.4M | 1.04% |
5,680,785
| – | – |
2021 Q3
9 quarters
|
|
13
Relay Therapeutics
RLAY
$3.74B
| $17.3M | 0.8% |
1,568,753
| – | – |
2020 Q3
13 quarters
|
|
|
14
Oscar Health
OSCR
$10.6B
| $14.9M | 0.69% |
1,629,087
-12,848,287
| -89% | -$88.7M |
2021 Q1
11 quarters
|
|
15
DELISTED
RAPT Therapeutics
RAPT
| $13.4M | 0.62% |
67,534
| – | – |
2019 Q4
16 quarters
|
|
16
Sana Biotechnology
SANA
$698M
| $11.5M | 0.53% |
2,812,500
| – | – |
2021 Q1
11 quarters
|
|
17
Lyell Immunopharma
LYEL
$196M
| $11.4M | 0.53% |
293,256
| – | – |
2021 Q2
10 quarters
|
|
18
Beam Therapeutics
BEAM
$2.44B
| $8.75M | 0.41% |
321,604
| – | – |
2020 Q1
15 quarters
|
|
19
DELISTED
Desktop Metal, Inc.
DM
| $8.29M | 0.38% |
1,104,873
| – | – |
2020 Q4
12 quarters
|
|
20
Monte Rosa Therapeutics
GLUE
$839M
| $8.27M | 0.38% |
1,464,015
| – | – |
2021 Q2
10 quarters
|
|
21
Illumina
ILMN
$41B
| $7.45M | 0.35% |
54,967
| – | – |
2021 Q3
9 quarters
|
|
|
22
Neumora Therapeutics
NMRA
$66.6M
| $6.9M | 0.32% |
404,732
+205,124
| +103% | +$2.52M |
2023 Q3
1 quarter
|
|
23
TScan Therapeutics
TCRX
$14.3M
| $6.28M | 0.29% |
1,077,080
| – | – |
2021 Q3
9 quarters
|
|
|
BRNS
24
DELISTED
Barinthus Biotherapeutics
BRNS
| $5.59M | 0.26% |
1,513,644
| – | – |
2021 Q2
10 quarters
|
|
25
Vera Therapeutics
VERA
$1.93B
| $4.64M | 0.22% |
301,580
| – | – |
2021 Q2
10 quarters
|
|
Similar funds
Alphabet Inc's Q4 2023 Portfolio in Review
As of Q4 2023, Alphabet Inc held 46 positions worth $2.16B, up 39% from $1.56B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Alphabet Inc deployed $129M of net new capital in Q4 2023, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Revolution Medicines: 5,301,512 shares worth $152M.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 39% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was UiPath, an estimated $137M trimmed.
- Alphabet Inc's largest Q4 2023 buy was Revolution Medicines: 5,301,512 shares worth $152M.
- Alphabet Inc added most to DexCom in Q4 2023, an estimated $309M increase.
- Alphabet Inc's biggest Q4 2023 reduction was UiPath, cutting an estimated $137M.
- Alphabet Inc fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $106M.
- Alphabet Inc's ten largest holdings make up 88% of its $2.16B portfolio in Q4 2023.
- Alphabet Inc opened 1 new position and closed 2 in Q4 2023.
- Alphabet Inc's portfolio value rose 39% quarter-over-quarter to $2.16B.
Based on Alphabet Inc's 13F filing for Q4 2023, filed 9 Feb 2024.